Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells
Cytotoxicity, Immunologic
Interleukin-15
0301 basic medicine
Cell Death
Egg Proteins
Epitopes, T-Lymphocyte
Cell Differentiation
Mice, Transgenic
Dendritic Cells
CD8-Positive T-Lymphocytes
Lymphocyte Activation
Adoptive Transfer
Immunophenotyping
3. Good health
Mice, Inbred C57BL
Mice
03 medical and health sciences
Adjuvants, Immunologic
Injections, Intravenous
Animals
Humans
Immunologic Memory
Injections, Intraperitoneal
DOI:
10.4049/jimmunol.169.9.4928
Publication Date:
2014-04-21T00:57:06Z
AUTHORS (6)
ABSTRACT
The systemic administration of IL-2 can act as a potent adjuvant for T cell-directed vaccine strategies. However, not only is the potentially toxic, but recent evidence suggests that it may also paradoxically limit duration and magnitude cytotoxic cell response. A recently identified cytokine, IL-15, shares many properties with provide preferential means augmenting responses. Although well characterized in vitro, there are few data on ability IL-15 to augment cell-mediated responses vivo. We therefore evaluated function murine model. To establish population easily identifiable Ag-responsive cells, naive CD8(+) (OT-1) cells were first adoptively transferred into mice. Vaccination peptide-pulsed dendritic induced modest expansion OT-1 cells. addition 7 days following vaccination resulted significant increase responding PBL, spleen, lymph nodes. Importantly, maintained Tc1-biased phenotype. did observe either enhanced resistance activation-induced death or generation memory result treatment compared IL-2. These studies show time capable primary response contribute basis future experiments exploring clinical role IL-15.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (92)
CITATIONS (72)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....